Transcription of Presentation - What to control? CQAs and CPPs
{{id}} {{{paragraph}}}
Example: stock market
Presentation - What to control? CQAs and CPPs
1 | Martin Schiestl | Singapore, 27 November 20101 what to control ? cqas and CPPsDr. Thomas StanglerOn behalf of the European Generic medicines AssociationDevelopment Strategy & Technology ManagerSandoz BiopharmaceuticalsBWP Workshop on Setting SpecificationsLondon, 9 September 20112 | what to control ?, BWP Workshop on Setting Specifications | Thomas Stangler, September 9th, 2011 Agenda Critical Quality Attributes ( cqas ) Scoring Impact and Uncertainty Uncertainty Dilemma Continuous quality attribute critical scale Critical process Parameters ( cpps ) process control point analysis High level overview on process product linkage FMEA risk assessment as life cycle approach Considering process parameter range cqas and cpps as basis for the control strategy3 | what to control ?
• Process control point analysis ... e.g. by linking CQAs to process capability and detectability ... CQAs are a key concept for a pharmaceutical product development. Regulatory landscape for CQAs. ICH Q8(R2) “At a minimum, those aspects of drug substances [...] that are critical to ...
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Analysis, Design/Build vs. Design-Bid-Build, Capability, Process, Pharmaceutical, Process Capability, Process analysis, Journal of Pharmaceutical and Biomedical Analysis, PROCESS CAPABILITY ANALYSIS IN PHARMACEUTICAL, PROCESS CAPABILITY ANALYSIS IN PHARMACEUTICAL PRODUCTION, Residual Solvents: ICH Q3C Impurities: Residual, In pharmaceutical